These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1355 related articles for article (PubMed ID: 34529955)

  • 41. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
    Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
    Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
    J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
    Scott LJ
    Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
    Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
    Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
    Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
    Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
    Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
    Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S
    Blood; 2017 Aug; 130(8):974-981. PubMed ID: 28637662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
    Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
    Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
    Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
    Mai EK; Goldschmid H; Miah K; Bertsch U; Besemer B; Hänel M; Krzykalla J; Fenk R; Schlenzka J; Munder M; Dürig J; Blau IW; Huhn S; Hose D; Jauch A; Kunz C; Mann C; Weinhold N; Scheid C; Schroers R; von Metzler I; Schieferdecker A; Thomalla J; Reimer P; Mahlberg R; Graeven U; Kremers S; Martens UM; Kunz C; Hensel M; Benner A; Seidel-Glätzer A; Weisel KC; Raab MS; Salwender HJ;
    Lancet Haematol; 2024 Feb; 11(2):e101-e113. PubMed ID: 38302221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
    Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
    Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
    J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
    Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA; Lonial S; Yu Z; Patin J; Olesnyckyj M; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2133-42. PubMed ID: 18032763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.